Colchicine sensitizes human hepatocellular carcinoma cells to damages caused by radiation

World Journal of Gastroenterology

Volumn 11, Issue 27, 2005, Pages 4237-4240

  Liu, Chia Yuan ^a   Liao, Hui Fen ^a,c,d   Shih, Shou Chuan ^a,b   Lin, Shee Chan ^a   Chang, Wen Hsiung ^a   Chu, Cheng Hsin ^a   Wang, Tsang En ^a   Chen, Yu Jen ^a,c  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^c CHINESE CULTURE UNIVERSITY   (Taiwan)

^d NATIONAL CHIAYI UNIVERSITY   (Taiwan)

Author keywords

Colchicine; Hepatocellular carcinoma; Radiation sensitizer

Indexed keywords

COLCHICINE; RADIOSENSITIZING AGENT;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RADIOTHERAPY; CARCINOMA CELL; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE PHASE; CELL DAMAGE; CELL FRACTIONATION; CELL KILLING; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG MEGADOSE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LINEAR SYSTEM; LIVER CELL CARCINOMA; LOW DRUG DOSE; MATHEMATICAL MODEL; RADIATION DOSE; RADIOSENSITIZATION; SURVIVAL RATE; TUMOR CELL LINE;

EID: 23144458299     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i27.4237     Document Type: Article

References (23)

1. Ben-Chetrit E, Levy M. Colchicine: 1998 update. Semin Arthritis Rheum 1998; 28: 48-59
2. Emmerson BT. The management of gout. N Engl J Med 1996; 334: 445-451
3. Yu TF, Gutman AB. Efficacy of colchicine prophylaxis in gout. Prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects. Ann Intern Med 1961; 55: 179-192
4. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet 1989; 1: 1093-1096
5. Floreani A, Lobello S, Brunetto M, Aneloni V, Chiaramonte M. Colchicine in chronic hepatitis B: a pilot study. Aliment Pharmacol Ther 1998; 12: 653-656
6. Lee YM, Kaplan MM. Efficacy of colchicine in patients with primary biliary cirrhosis poorly responsive to ursodiol and methotrexate. Am J Gastroenterol 2003; 98: 205-208
7. Wallace SL, Singer JZ. Review: systemic toxicity associated with the intravenous administration of colchicine-guidelines for use. J Rheumatol 1988; 15: 495-499
8. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002; 35(5 Suppl 2): S72-S78
9. Faivre J, Forman D, Esteve J, Obradovic M, Sant M. Survival of patients with primary liver cancer, pancreatic cancer and biliary tract cancer in Europe. Eur J Cancer 1998; 34: 2184-2190
10. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001; 33: 62-65
11. Nguyen MH, Keeffe EB. Treatment of Hepatocellular cancer. In: Rustgi AK, Crawford JM. Gastrointestinal Cancers. London: Saunders 2003: 615
12. Cheng SH, Lin YM, Chuang VP, Yang PS, Cheng JC, Huang AT, Sung JL. A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 1999; 14: 1025-1033
13. Park HC, Seong J, Han KH, Chon CY, Moon YM, Suh CO. Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2002; 54: 150-155
14. Sinclair WK, Morton RA. X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 1966; 29: 450-474
15. Lin YM, Hu CP, Chou CK, Lee TW, Wu KT, Chen TY, Peng FK, Lin TJ, Ko JL, Chang CM. A new human hepatoma cell line: establishment and characterization. Zhonghua Minguo Weisheng Wuji Mianyixue Zazhi 1982; 15: 193-201
16. Chang C, Lin Y, Lee TW, Chou CK, Lee TS, Lin TJ, Peng FK, Chen TY, Hu CP. Induction of plasma protein secretion in a newly established human hepatoma cell line. Mol Cell Biol 1983; 3: 1133-1137
17. Hall EJ. Cell survival curves. In: Radiobiology for the radiologist. 5 th ed. Philadelphia: Lippincott Williams & Wilkins 2000: 32-37
18. Kuban DA, Dong L. High-dose intensity modulated radiation therapy for prostate cancer. Curr Urol Rep 2004; 5: 197-202
19. Olmi P, Fallai C, Cerrotta AM, Lozza L, Badii D. Breast cancer in the elderly: the role of adjuvant radiation therapy. Crit Rev Oncol Hematol 2003; 48: 165-178
20. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991; 21: 109-122
21. Alsowmely AM, Hodgson HJ. Non-surgical treatment of hepatocellular carcinoma. Aliment Pharmacol Ther 2002; 16: 1-15
22. Wu DH, Liu L, Chen LH. Radiosensitization by pentoxifylline in human hepatoma cell line HepG2 and its mechanism. Diyi Junyi Daxue Xuebao 2004; 24: 382-385
23. Paris R, Morales A, Coll O, Sanchez-Reyes A, Garcia-Ruiz C, Fernandez-Checa JC. Ganglioside GD3 sensitizes human hepatoma cells to cancer therapy. J Biol Chem 2002; 277: 49870-49876